Monday, 13 April 2020

Global Healthcare Revenue Cycle Management Market Positive Growth And Forecasts By 2027


Market Scenario
Market Research Future Published a Cooked Research Report on Healthcare Revenue Cycle Management Market Research Report – Forecast to 2027.
Healthcare revenue cycle management (RCM) is a software that manages and simplifies all administrative and clinical functions including claims process, payment, revenue generation, patient registration, medical documentation, insurance verification, and accounts receivable & collections. Healthcare revenue cycle management software has gained profound importance in the healthcare sector in recent years. The global healthcare revenue cycle management market is anticipated to register a CAGR of 12.2% over the forecast period of 2017-2027, asserts Market Research Future (MRFR) in a detailed research report.
Towering costs of surgeries and overall healthcare has prompted hospitals to resort to technologies to reduce burden. Simplification of financial transactions is a key growth motivator which has spurred the adoption of RCM software among hospitals. In addition, expansion of healthcare budget and increase in a number of hospital chains and healthcare services across the globe fares well for the market. RCM software allows healthcare institutions to not only increase accuracy and timeliness but also helps them adhere to continuously evolving regulatory norms. RCM software can be applied to every aspect of the revenue cycle and is gaining traction among healthcare institutions.
On the downside, the growth of the global healthcare revenue cycle management market might be deterred by a dearth of trained healthcare professionals to operate the software. The global healthcare revenue cycle management market is anticipated to reach USD 1,75,163.5 Mn by the end of 2027.
Key Players for Global Healthcare Revenue Cycle Management (RCM) Market
·         Epic Systems Corporation (US),
·         McKesson Corporation (US),
·         Cerner Corporation (US),
·         General Electric Company (US),
·         Allscripts (US),
·         Quest Diagnostic (US),
·         Siemens Healthcare (Germany),
·         AdvantEdge Healthcare Solutions (US),
·         CareCloud (US),
·         Acelerartech (US),
·         3M (US).

Intended Audience
  • Healthcare Revenue Cycle Management (RCM) Products Manufacturers
  • Healthcare Revenue Cycle Management (RCM) Products Providers
  • Medical Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Segmentation                                                                                                                                 
The global healthcare RCM market is segmented on the basis of deployment, component, product types, and end users.
On the basis of deployment, the market is segmented into on-premises, and cloud-based.
On the basis of component, the market is categorized into services, and software.
On the basis of product types, the market is divided into integrated software, and standalone software.
On the basis of end users, the market is shared into hospitals, ambulatory services and others.

Posted by at No comments:

Enema Based Products Market Competitors Analysis: Till 2023

Market Synopsis of the Global Enema Based Products Market
The global enema based products market is expected to show sharp growth over the forecast period. Rising Enema Based Products Market demand and prevalence of gastrointestinal disorders such as constipation across the globe, availability of various types of enema administration kits such as cleansing and carminative enema and overall demand for enema administration products drivers the market growth.
Enema based products are used to remove waste for the rectum and can be used at home as a remedial measure for constipation and other gastrointestinal disorders. Constipation is a major gastrointestinal condition, found to be prevalent across the globe. Other condition that may require enema administration are obesity, diabetes, and cancer. 
Risk involved in the use of enema based product is irritation in the rectum and embolism, in case of incorrect use of enema administration
According to the latest 2016 data from the World Health Organization, an estimated 422 million adults were living with diabetes mellitus across the globe.
The global enema based products market is expected to grow at a CAGR of 10.2% during the forecast period.
Key Players
Some of the key players in this market are Baxter International, Inc. (U.S), MacoPharma (U.K),  Hollister Incorporated  (U.S), Coloplast Group (Germany), Medline Industries, Inc. (U.S), and B Braun Melsungen AG (Germany).
Segments 
The global enema based products market is segmented on the basis of administration type, indication, preparation, and end users.
On the basis of administration type, market is segmented into cleansing enema, carminative enema, retention enema, return-flow enema, and others. Cleansing enema is further segmented into large volume enema, small volume enema, and prepackaged disposable enema. Retention enema is further segmented into oil enema, sedative enema, nutrient enema, anesthetic enema, medicinal enema, and others.
On the basis of indication, the market is market is segmented into constipation, diarrhea, obesity, cancer and others.
On the basis of preparation, the market is divided into sodium phosphate enemas, coffee enemas, barium enemas, water-soluble contrast enemas and others.  Barium enemas is further segmented into single-column barium enema and double-contrast barium enema.
On the basis of end user, the market is divided into hospitals or clinics, home, and others. 
Regional Analysis
The global enema based products market size by regional basis is segmented into regions namely Americas, Europe, Asia Pacific and the Middle East & Africa. America is the largest market for enema based products owing to increasing use of enema based products at home, and rising demand for enema kits by healthcare providers. According to the Canadian Journal of Gastroenterology, constipation is a common problem among the people in the North American region. One of the study stated that the 20% of the North American population suffer from constipation.
Europe is the second largest market owing rise in the number of enema administration procedures in the hospitals. Rising prevalence of constipation, diarrhea, and obesity also contributes to the progress of the market. Prevalence of diabetes is also found to be increasing in the Europe. According to the World Health Organization, nearly 60 million people with diabetes in the European Region and the prevalence is higher among people aging 25 years and above.
In Asia Pacific, the prevalence of chronic diseases such as diabetes and obesity is found to be increasing. Diabetes is one of the major problem in China and India. India has world’s second largest population of diabetic patients, around 69.2 million in 2015 and that are expected to increase to 123.5 million by 2040. The number of undiagnosed diabetes is higher in India which was around 36 million in 2015.
The Middle East & Africa also shows a steady rise in the market owing to lack of physical exercise, increasing problem of constipation and availability of enema based products in the market.
Posted by at No comments:

Global Cardiac Valve Market Outlook, Key Financials, Segmental Revenue And Geographical Revenue Till 2023

Market scenario
An expert on premium research reports, Market Research Future asserts that, Global Cardiac Valve Market is expected to grow at a CAGR of 11.5% during the forecasted period.
Cardiac valve or heart valve allows blood to flow in only one direction through the heart. Human heart consists of four valves. These valves open and closes compulsory on differential blood pressure on each side.
Furthermore, valve replacement remains the most widely used technique but the proportion of valve repair procedures is increasing in experienced treatment centres. Moreover, increasing development in medical technology and its wide range of application used in the treatment of various cardiac diseases will fuel the growth of the market. However, high cost of the treatment likely to restrain the growth of the market over the assessment period. The global cardiac valve market growth is expected to grow at a CAGR of 11.5% during the forecast period.

Key players
Medtronic (U.S.), Edwards Lifesciences Corporation (U.S.), Boston Scientific Corporation (U.S.), St. Jude Medical, Inc. (an Abbott Laboratories Company) (U.S.), LivaNova PLC (U.K), Symetis SA (Switzerland), Jenavalve Technology, Inc. (Germany), CryoLife, Inc. (U.S.), TTK HealthCare (India), Colibri Heart Valve, LLC (U.S.), Lepu Medical Technology Co., Ltd. (China), and Braile Biomédica (Brazil) are some of the prominent players at the forefront of competition in the Global Cardiac Valve Market and are profiled in MRFR Analysis. 
Segmentation

The global cardiac valve market is segmented on the basis of types, by diseases, by treatment, and by end users.
On the basis of treatments, it is segmented into valve replacement, valve repair, and others.

On the basis of types, the market is segmented into trans-catheter heart valve, tissue heart valve, mechanical heart valve, and others.
On the basis of disease, the market is segmented into aortic valve replacement, heart valve disease, mitral valve stenosis, and others.
On the basis of end users the market is segmented into cardiac research institute, hospital & clinics, and others.
Regional analysis
The Americas mainly include North America and South America of which North America dominates the market owing to the presence of huge number of patient with cardiac diseases, increasing geriatric population, and increasing healthcare expenditure.  
In Asia Pacific, increasing government support for research & development in healthcare domain, growing number of cardiovascular diseases drive the growth of the market in this region.
Europe is the second highest revenue generating region in the cardiac valve market. Europe is mainly consist of Eastern Europe and Western Europe. More developed countries of Western Europe such as Germany, France, and the UK are holding the major market share, whereas the East European countries are also growing at a significant rate. Moreover, owing to developing healthcare infrastructure and increasing healthcare expenditure will boost the market growth in this region.
The Middle East & Africa is expected to show a least market share due to less availability of medical facilities, and less development in healthcare domain
Posted by at No comments:
Labels:

International Ophthalmic Suspension Market And Prominence 2023 On Consumer Needs, Revenue, Pricing Strategy And Growth Rate

Market Scenario
The global ophthalmic suspension market is expected to exhibit a strong 6.8% CAGR over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR). The report profiles the leading players in the global ophthalmic suspension market to provide readers with a clear picture of the major drivers and restraints affecting the market growth over the forecast period. The global ophthalmic suspension market is also analyzed with respect to its segmentation in order to pinpoint the leading segments likely to drive the market’s progress over the coming years.
The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a combination of two such as antibiotics and a corticosteroid for more effective treatment. Various bacterial eye infections such as conjunctivitis are treated by ophthalmic suspension.   
Increasing prevalence of eye diseases across the globe is one of the major factors contributing to the growth of this ophthalmic suspension market size. Moreover, increasing geriatric population which are most prone to eye disorders, and growing number of bacterial infections cases in children will also boost the growth of the market. Furthermore, according to WHO (2014), glaucoma is the second major cause of blindness in the world which will increase the market growth.
On the other hand, the side-effects of ophthalmic suspension may hamper the market growth during the corresponding period.
Key Players 
  • Novartis AG (Alcon)
  • ALLERGAN
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bausch & Lomb Incorporated
  • Falcon Group
  • Valeant
  • Bayer AG
  • Genentech, Inc.   
Segmentation
The global ophthalmic suspension market is segmented on the basis of type of content, which is segmented into antibiotic, antifungal, antibacterial, steroids, NSAIDs (non-steroidal anti-inflammatory drugs) and others.
On the basis of applications, it is segmented into bacterial infections, retinal disorders, glaucoma, allergies, diabetic eye disease, and others. Bacterial infection is further conjunctivitis, scleritis, and others. Retinal disorder is further segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital x-linked retinoschisis, and others.   
On the basis of end user, the market is segmented into hospitals, eye clinics, pharmacies, and others.
Regional Analysis
The American region accounted for the largest share of the global ophthalmic suspension market due to increasing prevalence of eye related diseases and increasing demand for new ophthalmic suspension for its treatment. Moreover, increasing geriatric population is another major factor responsible for the market growth in American countries.
In Asia Pacific, increasing government support for research & development in healthcare domain, growing number of ophthalmic clinics, and increasing prevalence of eye related diseases drives the growth of the market in this region.
Europe is the second largest ophthalmic suspension market across the globe owing to increasing awareness regarding eye related diseases, growing technological advancements in healthcare domain and increasing investment in healthcare domain by government.
The Middle East & Africa is expected to show a least market share due to less availability of medical facilities, and less development in healthcare domain.
Posted by at No comments:

TMJ Disorders Market Opportunities, Drivers, Manufacturers, Analysis And Forecasts Till 2023

Market Highlights
The global TMJ disorders market is growing moderately, and it is expected to grow at the same pace over the forecast period 2017-2018. Increasing number of patients affected by TMJ disorder is driving the market growth. Tissue engineering is considered as upcoming trend for treatment of this disorder. Ongoing research on tissue engineering is key driving force for the market growth. In 2015, the company named Renew Health Ltd. got regulatory approval for the use of Cerezen device in UK. This is new and innovative device that can used for the treatment of TMJ disorder.
The global market of TMJ disorders was around USD 940.3 million in 2016 and is expected to reach USD 1229.1 million by 2023 at a projected CAGR of 3.9%.
Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content TOC & market synopsis on “TMJ disorders market research report–Global forecast to 2023.”
Major Players in TMJ disorders Market
Some of the key market players: AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Jubilant Cadista (US), Pfizer Inc. (US), Sun Pharmaceutical Industries Ltd. (India), and others.
Regional Analysis
The global TMJ disorders market consists of four regions: Americas, Europe, Asia Pacific, and the Middle East & Africa.
The Americas dominate this market, particularly North America due to ongoing research and clinical trials. American pharmaceutical companies such as Pfizer Inc. are dominating the global healthcare sector, and these companies are investing a large amount of money for research. Upcoming healthcare bill in the US is expected to lead the market growth in this region. Growing awareness among Latin American population regarding this disorder is another key driver for this market.
Increasing incidence of TMJ disorders drives the European market. Moreover, availability of skilled medical professional and advanced healthcare facilities add fuel to the market growth. This region is mainly divided into Eastern Europe and Western Europe.
Asia Pacific is home to more than half of the world’s population. Increasing healthcare expenditure, government support to improve public health and growing awareness are driving this market. People are getting more aware about this disorder which also playing important role in the growth of the market.
Due to lack of awareness about this disorder and limited access to the healthcare facilities, the Middle East & Africa region is expected to have the least growth during the forecast period
Segmentation
The global TMJ disorders market is segmented on the basis of diagnosis, which includes physical exam, imaging tests, and others. Imaging tests plays important role in diagnosis of this disorder, these tests may include Computerized Tomography (CT) scan, X-rays, Magnetic Resonance Imaging (MRI), TMJ arthroscopy, and others.
On the basis of treatments, the market is segmented into medications, therapies, surgical or other procedures, alternative medicine, and others. Medications is sub-segmented into pain relievers, anti-inflammatories, tricyclic antidepressants, muscle relaxants, and others. Some therapies also help to cure this disorder such as Oral splints or mouth guards (occlusal appliances), physical therapy, counseling, and others. Some surgical or other procedures includes arthrocentesis, injections, TMJ arthroscopy, modified condylotomy, open-joint surgery, and others. Alternative medicine is also use for the treatment of this disorder such as acupuncture, relaxation techniques, biofeedback, and others.
On the basis of end user, it is segmented into hospitals & clinics, ambulatory surgery centers, academic institutes, medical research centers, and others.
Posted by at No comments:

Molecular Modelling Market Value Chain, Factor Analysis, Region And Forecasts Till 2023

Market Scenario
Molecular modelling comprises an array of computational techniques used in creation, manipulation, and representation of the various reactions and structures of molecules. Its applications included drug discovery and development but have since extended into computational chemistry and materials science. Rising use of molecular modelling by scientists to run multiple simulations can expedite the drug development process considerably.
The global molecular modelling market share is anticipated to expand at a 15.16% CAGR from 2018 to 2023 (forecast period), according to the latest report by Market Research Future (MRFR). Investments in R&D by pharmaceutical and biotechnology companies and prevalence of chronic diseases are factors certain to spur market growth over the forecast period.
According to the Brookings Private Sector Global Health R&D Project, nearly USD 159.9 Bn has been dispensed for healthcare R&D in developed and developing regions. Out of which, the majority can be credited to pharmaceutical companies. The booming biosimilars and biologics industry is bound to propel the market demand in the coming years. But the high R&D expenditure can impede market growth.
Report Overview
The report covers the latest trends affecting the market to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts make highly astute projections regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global molecular modelling market segmented by product, application, end-user, and region. Trends and opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.
Segment Overview
Products in the molecular modelling market include software and services. Major applications include drug discovery, drug development, and others. Drug discovery is sub-segmented into direct drug design, indirect drug design, and molecular mimicry. End-users of the market include research centers and academic institutions, pharmaceutical and biotechnology companies, and others.
The segments covered in the report are analyzed with respect to four major regions – Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition and advantages of “molecular modelling” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.
Competitive Landscape
Some of the key players in the molecular modelling market include Cresset, Acellera Ltd., Schrödinger, LLC, Optibrium, BioSolve-IT, Simulations Plus, Inc., Chemical Computing Group, Certara, L.P, OpenEye Scientific Software, Dassault Systèmes, Cambridge Crystallographic Data Centre, and others. New product launches and clinical trials are used to gauge the success of drugs. Various strategies such as acquisitions, partnerships, joint ventures, and distribution agreements are used by these players to gain a major share in the market.
The report offers comprehensive profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are discussed in granular detail.
Opportunity:
Countries situated near the equator have become the budding ground for many chronic diseases such as chagas, dengue, leprosy, and rabies due to problematic climactic conditions forcing these countries to employ the latest advancements into their system. Governments of developing countries have initiated education programs and projects such as the Janala Project in Bangladesh, ProjectABC in Nigeria, Tostan in Senegal, Yoza in South Africa, and BridgeIT in Tanzania, and others to create awareness regarding the conditions and healthcare IT tools.
Regional Analysis
The Americas dominates the global molecular modelling market owing to well-developed technology, increasing prevalence of the people suffering from cardiovascular diseases, and increasing government support for research & development. Furthermore, high healthcare expenditure and increasing R&D activities have fuelled the growth of the market in this region.
Europe holds the second position in the global molecular modelling market, which is followed by Asia Pacific. It is expected that the government support for research & development and availability of funds for research will drive the market. Asia Pacific is the fastest growing molecular modelling market due to the presence of rapidly growing economy, developing healthcare technology, increasing healthcare expenditure, and huge patient pool.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.
Posted by at No comments:

Global Drug Allergy Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Drug Allergy Market-Overview
Allergy is the sensitivity of immune system, which occurs when a foreign substance, harmless in nature react with the immune system. This substance is known as allergen. The common allergens are dust mist, pollen, mold, smoke and many more. According to the World Allergy Organization, approximately 30-40% of the global population is suffering from allergy. Many people are suffering from different types of allergy including seasonal allergy. Additionally, most of the people also suffer from drug allergy whose prevalence is found to be increasing across the globe. Treatment involves the use of antihistamines, corticosteroids, treatment of anaphylaxis, withdrawal of the drug, and others.
According to the American Academy of Allergy, Asthma & Immunology, about 5-10% of total American population is allergic to various medicines. Adverse reaction to various drugs or medicines is common in the U.S. population.  Some of the common medicines such as penicillin, aspirin, non-steroidal anti-inflammatory medications, anticonvulsants, chemotherapy, and monoclonal antibody therapy are more likely to trigger an allergic reaction in the patients. Increasing investment for research and introduction of new treatments are leading the market growth in this region.
Increasing awareness about various allergies, the introduction of the new treatment of products and rising demand from emerging markets drives the drug allergy market growth. New research to prevent drug allergies is another key driver for the market. The global drug allergy market is growing moderately and is expected to continue its growth over the forecast period.
According to the European Academy of Allergy and Clinical Immunology (EAACI), around 2.6% hospitalization happens due to adverse drug effects while the prevalence of drug allergy in the hospitalized patients is around 10% in the Europe.
Key Players in the Drug Allergy Market:
AstraZeneca (UK), Bayer (US), Circassia (US), HAL Allergy Group (the Netherlands), Johnson & Johnson Services, Inc. (US), MAGNA Pharmaceuticals, Inc. (US), Stallergenes Greer (UK), and others.
Key Developments:
Strategic approaches adopted help the major players in the market to sustain their growth and develop their business in various geographical areas across the globe. Agreements and collaborations, mergers and acquisitions, and new product launches are various strategies followed by the key players.  
AstraZeneca:
Founded in 1999, AstraZeneca is headquartered in Cambridge, England, is a multinational pharmaceutical and biopharmaceutical company. The company offers distinctive products in three major therapy areas that provide meaningful difference to patients includes oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.
  • July, 2017: AstraZeneca and Merck & Co., Inc. entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an innovative, first-in-class oral poly ADP ribose polymerase (PARP) inhibitor currently approved for BRCA-mutated ovarian cancer in multiple lines of treatment. The strategic collaboration is expected to further increase the number of treatment options available to patients.
Stallergenes Greer:
  • October, 2017: Stallergenes Greer announced the acquisition of Medic Savoure Limited, a well-established allergy immunotherapy (AIT) leader in Canada. The acquisition strengthens local presence of Stallergenes Greer as well as accelerates the company’s growth in Canada. The acquisition is also expected to increase cash flow allergy business that bolsters Stallergenes Greer’s North American operations. The company focus on expanding its business in allergy immunotherapy.
  • November, 2016: Stallergenes Greer announced a collaboration with the Sean N. Parker Center for Allergy and Asthma Research at Stanford University ("Stanford"). The main focu of collaboration is to identify potential biomarkers of Allergy Immunotherapy (AIT) efficacy. And to access the impact of peanut oral immunotherapy on biological parameters. The collaboration with the Sean N. Parker Centre for Allergy and Asthma Research at Stanford University will help to strengthen its research and development goals to determine new treatment of allergic patients.
  • July, 2014: Stallergenes Greer announced the acquisition of the entire share capital of ALERGO PHARMA S.R.L., an Argentinean allergen immunotherapy (AIT) company. This acquisition focuses on combination of two complementary dedicated allergen immunotherapy companies, to widen the range of products for diagnosis and treatment of patients suffering from allergic respiratory diseases. This acquisition establishes Stallergenes Greer among the top allergen immunotherapy pharmaceutical companies in Latin America thus expanding the company’s geographical presence.
Research by Key Payers in the Market:
HAL Allergy Group:
HAL is one of the major companies in drug allergy market, head quartered at Leiden, Netherlands.  In 1959, it was started as am small laboratory in the centre of Haarlem, the Netherlands. It products include allergy vaccines and diagnostic products. 
  • May, 2016: HAL Allergy had successfully completed a Phase I trial with its novel subcutaneous immunotherapy (SCIT) product for treatment of peanut allergy. The drug contains peanut allergens which was modified using proprietary technology to reduce their allergenicity.
Posted by at No comments:
Subscribe to: Comments (Atom)